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Abstract
Antimicrobial drug resistance remains a leading problem in modern healthcare, impacting on treatment options, mortality, infection con-
trol and economic issues. The introduction of new antimicrobial drugs has consistently been followed by the emergence of resistant
bacteria. This review aims to answer the question of whether clinical improvement is likely if treatment of Staphylococcus aureus infec-
tions is attempted with an antimicrobial drug against which resistance is expressed in vitro (RD). Over time, S. aureus has acquired a
broad range of antimicrobial resistance mechanisms, and methicillin-resistant S. aureus (MRSA) strains have become the most common
multidrug-resistant healthcare-related infection-causing bacteria in Europe. As intention-to-treat studies with an RD would be unethical,
only observational studies to evaluate the impact of RD therapy have been performed. Most of these studies bolster the assumption
that RD therapy offers no beneﬁt to the patient, but some do not show a detrimental effect. Limited antimicrobial treatment options
for severe, invasive infections caused by MRSA might tempt physicians to use antimicrobials to which in vitro resistance is reported by
the microbiological laboratory. Reasons for this non-evidence-based approach might include better pharmacokinetic/pharmacodynamic
parameters, lower toxicity and better bioavailability in speciﬁc compartments, and/or the assumption of increased in vivo susceptibility of
those microorganisms reported as resistant in vitro. In vitro resistance of a bacterium to a drug implies that exposing this bacterium to
that drug should result in a worse clinical outcome than would be obtained with a drug to which resistance has not been observed
(SD). As a counterpoint to in vitro resistance breakpoints, the concept of clinical breakpoints is therefore brieﬂy revisited in this review.
In a nutshell, no evidence has been published that S. aureus infections can be reliably treated with RDs, either as a single administration
or in combination therapy.
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Introduction
Antimicrobial resistance is one of the leading problems in
modern medicine worldwide, with serious impacts on treat-
ment options, infection-related mortality, infection control
and economic issues. In an endless cycle, the introduction of
new antimicrobials is shortly followed by the emergence of
resistant bacterial strains. This review aims to answer the
question of whether clinical improvement is likely or possible
when an infection caused by Staphylococcus aureus is treated
with an antimicrobial compound to which in vitro resistance
has been observed (henceforward, for simplicity, ‘RD’, for
‘resistant antimicrobial drug’).
S. aureus causes a high number of both human and animal
infections, so it is likely that apparently successful treatment
with inappropriate drugs may be thought to occur, for sev-
eral reasons. For example, the S. aureus isolate recovered
from the clinical specimen may not be the (only) causative
agent of the infection under treatment.
It may also sometimes be difﬁcult to differentiate among
S. aureus contamination, colonization and infection. Healing
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resulting from a signiﬁcant contribution by the patient’s
immune system despite an inadequate therapeutic interven-
tion may also occur. It should also be mentioned, however,
that treatment failure despite the use of antimicrobials to
which resistance has not been observed in vitro (hencefor-
ward, for simplicity, ‘SD’, for ‘susceptible antimicrobial drug’),
e.g. vancomycin [1,2], can also be observed in the clinical
daily routine of human and veterinary medicine, owing to
suboptimal pharmacokinetic parameters, underdosage or lack
of compliance.
The Global Burden of S. aureus Infections
and the Emergence of Resistant Strains
To elucidate the remarkable impact of S. aureus on individual
and public health, a short overview will be given on some
historical and recent aspects pertinent to this review.
S. aureus is one of the major causative agents of a wide
range of pyogenic infections, e.g. skin and soft tissue infec-
tions, endocarditis, osteomyelitis, pneumonia and sepsis, and
toxin-related syndromes. A recent European survey [3]
reported S. aureus in up to 27.5% of bloodstream infections
and in up to 19.3% of pneumonias acquired in intensive-care
units. As part of the complex microbial community of the
anterior nares, this species colonizes about 30% of the
healthy human population [4]. Although the majority of colo-
nized individuals will suffer no adverse effects caused by the
colonizing strain, colonization has been described as a major
source and risk factor for S. aureus bacteraemia and other
invasive infections [5,6].
As the success story of modern medicine, the mortality of
S. aureus bacteraemia of about 70% in 1937 in the pre-peni-
cillin era decreased to about 30% following the introduction
of penicillin in 1944. However, a ﬁrst temporary setback
caused by the advent of penicillinase-producing strains, which
became widespread around 1954, resulted in a transient
increase in S. aureus-caused mortality to 50%. After the dis-
covery of methicillin in 1959, mortality again decreased to
about 30% [7].
The ﬁrst methicillin-resistant S. aureus (MRSA) isolates
were reported in 1961 in England by Patricia Jevons, who
was examining, at the Staphylococcus Reference Laboratory,
a strain collection from routine clinical material obtained
between October and November 1960, the year of the
introduction of methicillin onto the market [8]. The emer-
gence of MRSA was a therapeutic disaster, because the mecA
gene-encoded additional penicillin-binding protein 2a is
non-susceptible to acylation by conventional b-lactam antibi-
otics, with the exception of recently developed MRSA-active
cephalosporins (ceftobiprole and ceftarolin). S. aureus has
acquired further resistance mechanisms for all other classes
of antimicrobial drugs available for human and animal treat-
ment, such as ﬂuoroquinolones, tetracyclines, lincosamides,
macrolides, aminoglycosides, glycopeptides, pleuromutilins
and oxazolidinones [9–11].
In 2007, MRSA was the most common multidrug-resistant
bacterium causing bloodstream, lower respiratory tract, skin
and soft tissue and urinary tract infections in the European
Union [12]. It was estimated that MRSA accounted for 44%
(n = 171 200) of these infections in Europe, 22% (n = 5400)
of attributable extra deaths, and 41% (n = 1 050 000) of
extra hospital days [12].
Results of the Literature Survey
A search on PubMed was conducted in December 2010,
with the keyword combinations aureus/treatment, aureus/
inadequate/treatment, aureus/paradox, and aureus/mic/suc-
cess. No publications were found that described the inten-
tional treatment of staphylococcal infections with an RD.
This is not surprising, as a randomized trial comparing RD
therapy with SD therapy would be unethical to perform.
It is nevertheless unavoidable in clinical practice that some
patients will receive inappropriate antimicrobial therapy. This
situation allows for retrospective or prospective observational
studies to evaluate the impact of inappropriate antimicrobial
therapy [13]. The major methodological problems compro-
mising this kind of study, especially confounding resulting from
unmeasured variables, have been discussed in detail elsewhere
[14]. Some analyses of this kind have already been published
[15–20], most of them adding support to the assumption that
inappropriate antimicrobial therapy has no beneﬁcial effect for
the patient. However, despite their limitations, one study
[16], and a less stringent second one [20], failed to show a
detrimental effect—such as increased mortality—of inappro-
priate antimicrobial therapy.
The ﬁrst study, by Zaragoza et al. [16], was limited to one
intensive-care unit and included all 166 cases of bacteraemia,
regardless of the causative microorganism; 39 (23.5%) of the
patients received an RD, i.e. empirical antimicrobial treat-
ment in the absence of identiﬁcation of the causative organ-
ism. Coagulase-negative staphylococci (CNS) (29.5%) and
Acinetobacter baumannii (27.3%) were the most frequently
isolated organisms in the RD group: only 4.5% of the isolates
were S. aureus (9.8% in the SD group). In this study,
multivariate analysis did not demonstrate an association
between mortality and inappropriate therapy, source of
infection, isolated microorganism, and nosocomial acquisition
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of bacteraemia. The only factor related to mortality was the
presence of septic shock at the time of bacteraemia
(OR 3.19, 95% CI 1.08–9.40, p 0.03). Hospital-attributable
mortality was the main outcome variable, and no ﬁxed time-
point for evaluation was set. The authors reported that the
RD group had a higher rate of nosocomial bacteraemia
(92.3% vs. 79.5%, p 0.66) and included fewer cases of severe
sepsis or septic shock (48.7% vs. 58.3%, p 0.293). The high
incidence (27.3%) of A. baumannii bacteraemia was attributed
to an outbreak of this species during the study period. The
RD group included a total of 13/44 (29.5%) episodes of bac-
teraemia caused by CNS, as compared with 21/152 (13.8%)
in the SD group. This was the only signiﬁcant difference con-
cerning the distribution of microorganisms between the
groups. As CNS are considered to cause a low increase in
mortality, of about 13.6% [21], this heterogeneous distribu-
tion, as well as the lower incidence of septic shock, might
have contributed to the absence of beneﬁt attributable to
appropriate therapy.
The second study, by Kim et al. [20], also from a single
centre, was a retrospective cohort study of 238 patients
with S. aureus bacteraemia: 117 (49%) received an RD and
121 (51%) received an SD. Multivariate analysis of the cohort
resulted in an OR of 1.39 (95% CI 0.62–3.15, p 0.42) for
mortality related to the RD. This publication also included a
matched case–control study (50 pairs). In this second part,
46% (23/50) of patients died in both the SD and RD groups.
The authors concluded that inappropriate therapy resulted in
only a slight tendency towards increased mortality in S. aur-
eus bacteraemia. Here, treatment outcome was assessed
12 weeks after onset of bacteraemia. The authors mentioned
that both study parts might have been underpowered to
detect a statistical difference, remarked on the high rate of
liver cirrhosis (44/238 patients, 18%), and discussed the pos-
sible limitations of their statistical approach in detail. They
described a trend towards higher mortality if the SD was
delayed for more than 48 h.
In contrast to these two studies, a recent systemic review
and meta-analysis of the efﬁcacy of appropriate empirical
antimicrobial therapy [22] concluded that RD treatment is
signiﬁcantly associated with increased mortality in prospec-
tive studies. However, the effect size is highly variable, owing
to the heterogeneous study designs, concerning outcome
deﬁnitions, risk factors included, and multivariable analysis
methods. This heterogeneity is the major reason for
inconclusive results on the precise efﬁcacy of appropriate
antimicrobial treatment, and should be more carefully con-
sidered in future studies, which should ideally adhere to the
STROBE (Strengthening the Reporting of Observational
Studies in Epidemiology) guidelines [23].
The Importance of Understanding the
Susceptibility Testing of Microorganisms
The implementation of in vitro data on a microorganism’s
susceptibility to antimicrobial agents, as obtained in the
microbiological laboratory, in clinical therapeutic strategies
is often challenging. To translate the MIC, a laboratory
parameter describing the behaviour of a given microorgan-
ism towards a speciﬁc compound, into something meaning-
ful for the clinician, the concept of susceptibility/resistance
breakpoints was developed [24,25]. At ﬁrst glance, this sys-
tem may seem to some extent intuitive, but the continuous
re-evaluation incorporated in its elaboration results in
periodically updated MIC–breakpoint combinations. Con-
sequently, the antimicrobial susceptibility breakpoints used
to deﬁne a bacterial isolate as either susceptible or resis-
tant are complex constructs of practical and theoretical
considerations [24,25].
It is useful to shortly review here why breakpoints change
over time—usually being lowered [26]—thus causing a bac-
terium that had been reported susceptible at one time-point
to be termed ‘resistant’ at a later one, without, of course, a
change in MIC.
Susceptibility can be deﬁned either with respect to the
population of bacteria existing before the presumed expo-
sure to a given antimicrobial drug, i.e. the wild-type popula-
tion, or with respect to the clinical outcome of infections
treated with that antimicrobial drug [13]. Breakpoints
deﬁned, for example, by EUCAST are based on these
two deﬁnitions (http://www.srga.org/Eucastwt/eucastdeﬁni
tions.htm). Non-wild-type resistance results from an
acquired or mutated gene not present in the wild-type pop-
ulation, and whose expression is manifested as resistance to
the drug tested. More detailed information on this sensitive
area is available on the EUCAST homepage. Bacteria are
then deﬁned as microbiologically resistant (non-wild-type)
by phenotypic tests, e.g. determination of the MIC, with
application of cut-off values inferred from the wild-type
population. These cut-offs, however, simply describe an
in vitro phenomenon, and are independent of the clinical
situation. On the other hand, clinical resistance is deﬁned as
antimicrobial activity associated with a high likelihood of
clinical failure. Here, too, phenotypic test systems are used
to categorize a bacterial isolate as clinically resistant or sus-
ceptible. Clinical breakpoints incorporate pharmacodynamic
and pharmacokinetic parameters, and evolve as more infor-
mation becomes available concerning bacterial resistance
mechanisms, and as drug dosing and administration change
[26].
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In both cases, it is assumed that exposing an infection-
causing microorganism to a drug to which it is susceptible
should result in a better clinical outcome than using a drug
to which it is resistant [25]. However, not every infected
patient beneﬁts from appropriate antimicrobial therapy, and
not every patient has an unfavourable outcome if treated
with an inappropriate drug, e.g. an antimicrobial drug to
which the microorganism is resistant.
The predictive value of antimicrobial resistance testing has
been summarized by the ‘90–60 rule’ [27]. This states that
approximately 90% of infections caused by susceptible iso-
lates will respond to treatment, whereas approximately 60%
of infections caused by resistant isolates or treated with
inappropriate antimicrobials will also respond to treatment.
This can be explained by the fact that susceptibility testing
and the resulting treatment encompass just a part of the
complex, patient-related situation of an ongoing infection.
For instance, in septic shock, the clinical situation of the
patient may have deteriorated to a point where elimination
of the causative bacterium is not sufﬁcient to alter the clini-
cal outcome [28]. Diseases triggered by secreted bacterial
toxins, such as diphtheria or tetanus, will also take their
course despite proper eradication of the toxin-producing
bacteria, once the toxins have been released. There is also
the phenomenon of ‘phenotypic’, i.e. observed during treat-
ment, resistance of a bacterium that has been determined to
be susceptible in vitro. This is related, for example, to the
formation of bioﬁlms on foreign-body surfaces or the forma-
tion of phenotypic subpopulations, such as small-colony vari-
ants, exhibiting host response and antimicrobial evasion
strategies that cannot be or had not been observed under
the speciﬁc conditions of in vitro testing [29–32]. Finally,
effective treatment of focal infections (e.g. empyema and
abscesses) requires surgical intervention, such as incision and
drainage, before any antimicrobial treatment can be effective.
MIC breakpoints for susceptibility testing are not ﬁxed
values. The initial breakpoints of a new substance are usually
higher than their later revisions. This re-evaluation is neces-
sary to incorporate the effects of newly discovered resis-
tance mechanisms, the changes in doses and indications, and
the development of new testing methods [26]. Existing
breakpoints might not detect important resistance mecha-
nisms, and might not correlate sufﬁciently with clinical out-
come. Breakpoints that are sensitive enough to detect these
mechanisms are usually lower than previous ones; for exam-
ple, the vancomycin breakpoint was lowered to 2 mg/L in
order to not report S. aureus strains that are intermediately
resistant to glycopeptides as susceptible [33]. Heteroresis-
tance of a bacterial strain has been described for several
staphylococcal species [34–36], further complicating the
picture. Heteroresistant strains contain subpopulations with
different MICs towards an antimicrobial compound, possibly
resulting in invalid testing results. It is possible that, in vitro,
the resistance mechanism is not fully expressed, rendering
the organism susceptible in the laboratory. Under in vivo con-
ditions, however, this may change and the resistant subpopu-
lation may come to the fore, resulting in clinical failure.
Actual breakpoints and testing strategies are aimed at identi-
fying these organisms as soon as possible.
Therapeutic Challenge
The limited antimicrobial treatment options for severe, inva-
sive infections caused by MRSA—i.e. basically vancomycin,
daptomycin, trimethoprim-sulphamethoxazole or linezo-
lid—are substances that are either less active than b-lactams
against staphylococci [37] or that have problems regarding
toxicity and pharmacokinetic/pharmacodynamic parameters
[38–41]. It is speciﬁcally this conundrum that might tempt
physicians to use antimicrobials that are reported as inappro-
priate by the microbiological laboratory, but that are not
hampered by the above unfavourable characteristics. As
infections caused by CNS are usually treated with the same
antibiotic drugs as infections caused by MRSA, identical
therapeutic problems arise. In the treatment of severe and
complicated S. aureus infections, a b-lactam agent (methicil-
lin-susceptible S. aureus infection) or a glycopeptide (MRSA
infection) is often combined with a second agent, in most
cases an aminoglycoside (preferably gentamicin, arbekacin
or netilmicin) or rifampicin, and less frequently fusidic acid
or fosfomycin. A more rapid bacteriological response is thus
expected, based on the synergistic interaction between the
two antimicrobial classes. In the case of vancomycin, this
combination practice emerged largely in response to the rec-
ognition of important shortcomings of this drug, such as
poor tissue and intracellular penetration [42].
The empirical background to the widespread use of the
combination of b-lactam or vancomycin with an aminoglyco-
side for the treatment of S. aureus infections is mainly
based on in vitro synergy studies, pharmacodynamic models
and animal models, dating mostly from the 1980s and
1990s, showing in vitro synergism, through the enhancement
of vancomycin’s early bactericidal activity [43–48]. However,
an in vitro study of non-high-level gentamicin-resistant
(HLGR) MRSA showed that indifference, rather than
synergism, can also occur [49]: there was no relationship
between the agar dilution MIC of gentamicin and the
occurrence of synergism against non-HLGR isolates. In
addition, none of the HLGR MRSA isolates demonstrated
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vancomycin–gentamicin synergism. Also, Rochon-Edouard
et al. [50] reported on an indifferent in vitro effect provided
by a vancomycin–netilmicin combination against tested
MRSA. In the context of their synergism study, Watanaku-
nakorn and Tisone [43] had stated in 1982 that, with
regard to synergism, there was ‘no difference’ between gen-
tamicin-resistant and gentamicin-susceptible strains; how-
ever, the respective data were not shown. Thus, this
unsubstantiated remark represents the only ‘hint’ of possi-
ble therapeutic efﬁcacy in the presence of resistance mech-
anisms, and is restricted to aminoglycosides as combination
partners. Up to now , there have been no controlled, ran-
domized trials demonstrating the superiority of a combina-
tion with aminoglycosides over vancomycin alone, and, in
particular, there are no reliable data concerning the use of
aminoglycosides for which non-susceptibility has been
observed in vitro as combination partners for cell wall-active
antimicrobials. On the contrary, recent comparative investi-
gations have not conﬁrmed the additive beneﬁt of amino-
glycosides [51]. Consequently, it was concluded in a recent
review by Deresinski [42] that the available data would not
appear to provide support for the use of such combinations
for initial deﬁnitive treatment of MRSA infection. Moreover,
the potential nephrotoxicity of gentamicin without evidence
of a therapeutic beneﬁt makes its administration difﬁcult to
recommend [52,53].
Conclusion
The overall answer to the question of whether there exists
a substantiated rationale for the treatment of all S. aureus
infections with antimicrobials determined in vitro to be inef-
fective has to be ‘no’. Those published studies concerning
the efﬁcacy of inappropriate antimicrobial therapy at least
support the notion that inappropriate antimicrobial therapy
might, indeed, not be an absolute disaster for the patient.
However, the published studies on this matter are very het-
erogeneous and report inconclusive results. Future observa-
tional studies focused on the efﬁcacy of antibiotic treatment
should follow a stringent protocol for set-up and reporting,
in order to produce comparable data.
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